Related Experiment Video
Updated: Jun 19, 2026
07:42
Chromosome Preparation From Cultured Cells
Published on: January 28, 2014
Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy
Sarah E McClelland1, Rebecca A Burrell, Charles Swanton
1Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London, UK.
Cell Cycle (Georgetown, Tex.)
|October 7, 2009
Summary
Chromosomal instability (CIN) drives genomic instability in solid tumors and resistance to treatments like taxanes. However, platinum agents, such as carboplatin, show promise in targeting CIN cancers.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Chromosomal instability (CIN) is a hallmark of most solid tumors, involving continuous chromosome number alterations.
- CIN contributes to genomic instability, drug resistance (especially to taxanes), and poor patient prognosis.
Purpose of the Study:
- To investigate the role of CIN in solid tumor progression and treatment resistance.
- To explore the potential of platinum agents, like carboplatin, as targeted therapies for CIN-positive cancers.
Main Methods:
- Review of existing literature on chromosomal instability and cancer genomics.
- Analysis of clinical data linking CIN status to treatment response and prognosis.
- Examination of preclinical data on platinum agent efficacy in CIN models.
Main Results:
- CIN is a significant driver of genomic instability in diverse solid tumors.
- CIN is strongly correlated with resistance to taxane-based chemotherapy.
- Emerging evidence suggests platinum agents, including carboplatin, may be effective against CIN-driven tumors.
Conclusions:
- Chromosomal instability is a critical factor in solid tumor development and therapeutic challenges.
- Targeting CIN with agents like carboplatin represents a promising strategy for improving outcomes in specific cancer patient populations.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...